A randomized, double-blind, placebo-controlled crossover study of coenzyme Q 10 therapy in hypertensive patients with the metabolic syndrome

American Journal of Hypertension

Volumn 25, Issue 2, 2012, Pages 261-270

  Young, Joanna M ^a,b   Florkowski, Christopher M ^a,c   Molyneux, Sarah L ^c   McEwan, Roberta G ^a   Frampton, Christopher M ^b   Nicholls, M Gary ^b   Scott, Russell S ^a,b   George, Peter M ^c  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

ambulatory blood pressure monitoring; arterial pressure; blood pressure; clinical trial; coenzyme Q10; hypertension; metabolic syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PLACEBO; SULFONYLUREA; UBIDECARENONE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART RATE; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

AGED; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TREATMENT OUTCOME; UBIQUINONE; VITAMINS;

EID: 84856035599     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.209     Document Type: Article

References (46)

1. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001; 20:591-598.
2. Yamagami T, Shibata N, Folkers K. Bioenergetics in clinical medicine. Studies on coenzyme Q10 and essential hypertension. Res Commun Chem Pathol Pharmacol 1975; 11:273-288.
3. Koska J, Syrova D, Blazicek P, Marko M, Grna JD, Kvetnansky R, Vigas M. Malondialdehyde, lipofuscin and activity of antioxidant enzymes during physical exercise in patients with essential hypertension. J Hypertens 1999; 17:529-535. (Pubitemid 29308563)
4. Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 2007; 21:297-306. (Pubitemid 46453530)
5. Pepe S, Marasco SF, Haas SJ, Sheeran FL, Krum H, Rosenfeldt FL. Coenzyme Q10 in cardiovascular disease. Mitochondrion 2007; 7 Suppl:S154-S167.
6. Hodgson JM, Watts GF. Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. Biofactors 2003; 18:129-136. (Pubitemid 38030707)
7. Yamagami T, Takagi M, Akagami H, Kubo SH, Toyama S, Okamoto T. Effect of coenzyme Q10 on essential hypertension: a double blind controlled study. In: Folkers K, Yamamura Y (eds). Biomedical & Clinical Aspects of Coenzyme Q. Elsevier Science Publishers BV: Amsterdam, North Holland, 1986, pp. 337-343.
8. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens 1999; 13:203-208. (Pubitemid 29137435)
9. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebocontrolled trial of coenzyme Q10 in isolated systolic hypertension. South Med J 2001; 94:1112-1117. (Pubitemid 34008302)
10. Digiesi V, Cantini F, Brodbeck B. Effect of coenzyme Q10 on essential arterial hypertension. Curr Ther Res 1990; 47:841-845. (Pubitemid 20151543)
11. Yamagami T, Shibata N, Folkers K. Bioenergetics in clinical medicine. VIII. Adminstration of coenzyme Q10 to patients with essential hypertension. Res Commun Chem Pathol Pharmacol 1976; 14:721-727.
12. Yamagami T, Shibata N, Folkers K. Study of coenzyme Q10 in essential hypertension. In: Folkers K, Yamamura Y (eds). Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Biomedical Press: North Holland, 1977, pp. 231-242.
13. Folkers K, Drzewoski J, Richardson PC, Ellis J, Shizukuishi S, Baker L. Bioenergetics in clinical medicine. XVI. Reduction of hypertension in patients by therapy with coenzyme Q10. Res Commun Chem Pathol Pharmacol 1981; 31:129-140. (Pubitemid 11173801)
14. Montaldo PL, Fadda G, Salis G, Tronci M, DiCesare R. Effects of the prolonged adminstration of coenzyme Q10 in borderline hyertensive patients: a hemodynamic study. In: Folkers K, Littarru GP, Yamagami T (eds). Biomedical & Clinical Aspects of Coenzyme Q. Elsevier Science Publishers: Amsterdam, North Holland, 1991, pp. 417-424.
15. Digiesi V, Cantini F, Bisi G, Guarino GC, Oradei A, Littarru GP. Mechanism of action of coenzyme Q10 in essential hypertension. Curr Ther Res 1992; 51:668-672.
16. Digiesi V, Cantini F, Oradei A, Bisi G, Guarino GC, Brocchi A, Bellandi F, Mancini M, Littarru GP. Coenzyme Q10 in essential hypertension. Mol Aspects Med 1994; 15 Suppl:s257-s263.
17. Langsjoen P, Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994; 15 Suppl:S265-S272.
18. Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev 2009; CD007435.
19. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366:1059-1062. (Pubitemid 41338752)
20. Molyneux S, Florkowski C, Lever M, George P. The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly. N Z Med J 2004; 117:U1108.
21. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves JW, Hill MN, Jones DH, Kurtz T, Sheps SG, Roccella EJ; Council on High Blood Pressure Research Professional and Public Education Subcommittee, American Heart Association. Recommendations for blood pressure measurement in humans: an AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. J Clin Hypertens (Greenwich) 2005; 7:102-109.
22. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P; European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23:697-701. (Pubitemid 40523262)
23. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; . 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187. (Pubitemid 46924065)
24. Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Staessen JA; IDACO investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Blood Press Monit 2007; 12:393-395.
25. Molyneux S, Florkowski C, McGrane Y, Lever M, George P. Concentration response to the coenzyme Q10 supplement Q-Gel in human volunteers. Nutr Res 2007; 27:307-312. (Pubitemid 46962178)
26. Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002; 56:1137-1142. (Pubitemid 35414801)
27. Chew GT, Watts GF, Davis TM, Stuckey BG, Beilin LJ, Thompson PL, Burke V, Currie PJ. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008; 31: 1502-1509.
28. Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000; 35:844-851. (Pubitemid 30165336)
29. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 2002; 20:2183-2189. (Pubitemid 35388236)
30. White WB, Dey HM, Schulman P. Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild-to-moderate hypertension. Am Heart J 1989; 118:782-795. (Pubitemid 19242576)
31. Chughtai I, Peixoto A. Ambulatory blood pressure monitoring: a review of its clinical and prognostic relevance. Hospital Physician 2003; 62:47-56. (Pubitemid 36374256)
32. Zachariah PK, Sheps SG, Ilstrup DM, Long CR, Bailey KR, Wiltgen CM, Carlson CA. Blood pressure load-a better determinant of hypertension. Mayo Clin Proc 1988; 63:1085-1091.
33. Grossman E, Alster Y, Shemesh J, Nussinovitch N, Rosenthal T. Left ventricular mass in hypertension: correlation with casual, exercise and ambulatory blood pressure. J Hum Hypertens 1994; 8:741-746. (Pubitemid 24319385)
34. Tsioufis C, Stefanadis C, Goumas G, Pitsavos C, Toutouzas P. Relation of ambulatory blood pressure load with left ventricular geometry in untreated patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13:677-682. (Pubitemid 29481487)
35. Andrade SS, Serro-Azul JB, Nussbacher A, Giorgi D, Pierri H, Gebara O, Wajngarten M. Daytime systolic blood pressure load and previous stroke predict cardiovascular events in treated octogenarians with hypertension. J Am Geriatr Soc 2010; 58:2232-2234.
36. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B; Blood Pressure Lowering Treatment Trialists' Collaboration. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2011; 29:4-16.
37. Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens 2009; 27:1863-1872.
38. Hansen TW, Thijs L, Li Y, Boggia J, Kikuya M, Björklund- Bodegård K, Richart T, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Imai Y, Wang J, Ibsen H, O'Brien E, Staessen JA; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension 2010; 55:1049-1057.
39. Ikematsu H, Nakamura K, Harashima S, Fujii K, Fukutomi N. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial. Regul Toxicol Pharmacol 2006; 44:212-218.
40. Langsjoen PH, Langsjoen PH, Folkers K. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. Int J Tissue React 1990; 12:169-171. (Pubitemid 20370354)
41. Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994; 15 Suppl:s287-s294.
42. Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 2004; 188:491-494. (Pubitemid 38891609)
43. Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H; German Coenzyme Q(10) Study Group. Randomized, doubleblind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 2007; 64:938-944. (Pubitemid 47047992)
44. Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 1996; 11:321-323. (Pubitemid 26138832)
45. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001; 57:397-404.
46. Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 2005; 65:1834-1836.